MONROVIA, Calif., April 23, 2014 /PRNewswire/ -- STAAR Surgical
Company (NASDAQ: STAA), a leading developer, manufacturer and
marketer of implantable lenses and delivery systems for the eye,
today announced that it is hosting an investor breakfast and
webcast on Saturday, April 26 during
the ASCRS Symposium on cataract and refractive surgery in
Boston, MA.
The meeting will feature presentations by two leading
ophthalmologists who spoke at the recent FDA Ophthalmic Devices
Panel meeting at which the STAAR Visian® Toric Implantable
Collamer Lens (TICL) received a favorable vote on safety and
effectiveness. Dr. Gregory D.
Parkhurst, a cornea specialist at the Parkhurst
Nuvision Clinic in San Antonio,
and former Chief of Ophthalmology and Refractive Surgery at the
world's largest military base will speak on how he has used the
Visian ICL™ in his practice and in his military experience.
Dr. Robert P. Rivera, Director of
Clinical Research at the Hoopes Vision Center outside of
Salt Lake City, will speak on the
unmet need in the U.S. market for the TICL and how he plans to use
it in his practice once available.
Robin Hughes, Vice President of
Research and Development, will present on the new Preloaded ICL and
the V6 projects utilizing the proven ICL platform with enhanced
optical designs to treat and delay the onset of presbyopia.
Barry G. Caldwell, President and
CEO, will provide a brief update on the Company's operational
progress, as well as highlights from the recent FDA Ophthalmic
Devices Panel meeting.
Investors participating in ASCRS and interested in attending the
breakfast meeting should contact Leigh
Salvo at lsalvo@evcgroup.com or call (415) 568-9348. A
live audio webcast of the presentation will be available at
4:30 a.m. PT/7:30 a.m. ET from the investor section of the
Company's website at www.staar.com/html/investor-info.html. The
webcast will also be archived and available for 90 days following
the event.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 25 years, designs, develops, manufactures and markets
implantable lenses for the eye and delivery systems therefor. All
of these lenses are foldable, which permits the surgeon to insert
them through a small incision. STAAR's lens used in refractive
surgery as an alternative to LASIK is called an Implantable
Collamer® Lens or "ICL." A lens used to replace the natural lens
after cataract surgery is called an intraocular lens or "IOL." More
than 425,000 Visian ICLs have been implanted to date; to learn more
about the ICL go to: www.visianinfo.com. STAAR has approximately
335 full time employees and markets lenses in over 60 countries.
Headquartered in Monrovia, CA, it
manufactures in the following locations: Nidau, Switzerland; Aliso
Viejo, CA; and Monrovia,
CA. For more information, please visit the Company's website
at www.staar.com.
CONTACT:
|
Investors
|
Media
|
|
EVC Group
|
EVC Group
|
|
Doug Sherk,
415-652-9100
|
Nicole
Kruse
|
|
Leigh Salvo,
415-568-9348
|
646-688-0425
|
SOURCE STAAR Surgical Company